ABSTRACT PURPOSE: To evaluate the long-term side effects of mitomycin C (MMC) assisted photorefractive keratectomy (PRK) on corneal keratocytes of highly myopic eyes.
RESULTS:
Photorefractive keratectomy reduced keratocyte density in the most anterior stromal layer, without a statistically signifi cant difference between MMC and standard treated eyes. Posterior stromal layers showed no signs of keratocyte loss with either techniques.
CONCLUSIONS: Phototherapeutic keratectomy with 0.02% topical MMC has no signifi cant side effects on corneal keratocytes compared to standard PRK, as documented by in vivo corneal confocal microscopy. [J Refract Surg. 2007 ;23:S1011-S1014.] E xcimer laser photorefractive keratectomy (PRK) continues to have a relevant role in the surgical correction of refractive errors, particularly in eyes more prone to detrimental side effects after LASIK (eg, lower corneal thickness and high myopia). 1, 2 Highly myopic eyes, which need signifi cant volumes of tissue removed to correct the refractive error, seem the best candidates for PRK. Unfortunately, correction of high myopia with PRK leads to haze development, compromising fi nal visual function. To overcome the development of stromal haze, the prophylactic use of topical mitomycin C (MMC) during PRK has been successfully advocated. [3] [4] [5] Gambato et al 4 reported that topical MMC signifi cantly lowers the incidence of haze in highly myopic eyes compared to standard corticosteroid treatment. Recently, the use of topical MMC for corneal haze prevention has been cautioned because of presumed long-term side effects of this topically applied drug. 6 The aim of this study is to report the in vivo long-term effects, quantifi ed by corneal confocal microscopy, on corneal keratocytes of eyes that underwent PRK with topical MMC for the correction of high myopia compared to fellow eyes that underwent standard PRK treatment without MMC.
PATIENTS AND METHODS

PATIENTS AND STUDY DESIGN
This prospective, randomized, double-masked study comprised 28 patients (56 eyes) with bilateral high myopia (defi ned as у7.00 diopters [D]) who underwent PRK treatment with MMC in one eye and PRK treatment without MMC in the fellow eye. All eyes underwent corneal confocal microscopy at baseline and 5 years after bilateral PRK. To circum-vent any signifi cant differences in the amount of tissue removed between eyes, only patients with a baseline difference of Ͻ0.75 D bilaterally were included. At baseline, one eye was randomly assigned, per a randomization schedule, to receive topical MMC treatment, and the fellow eye was treated without MMC. This contralateral eye study approach was chosen to limit the infl uence of wound-healing characteristics on the study.
This study was approved by the institutional review board of Padova University Hospital. Prior to participating in the study, each patient signed a detailed informed consent that outlined the risks and benefi ts of the study. This study was double masked during surgery and follow-up. Inclusion criteria were preoperative myopia у7.00 D, best spectacle-corrected visual acuity (BSCVA) of 20/25 or better in both eyes, normal corneal topography, and stable manifest refraction as documented by a Ͻ0.50-D change in manifest refractive spherical equivalent shift within the 12 months prior to surgery. Contact lens wearers had to refrain from lens use prior to baseline examination-at least 2 weeks for soft/gas permeable lenses and 3 weeks for hard contact lenses.
Exclusion criteria were keratoconus, keratoconus suspect, active ocular disease or corneal abnormality, systemic disease likely to affect wound healing, unstable keratometry readings with irregularly shaped mires, use of systemic medications likely to affect wound healing, immunodefi ciency, previous intraocular or corneal surgery, glaucoma or glaucoma suspect, and corneal thickness that would require ablation within 300 µm of the endothelium.
SURGERY AND POSTOPERATIVE FOLLOW-UP
The operative and postoperative protocols have been described in detail previously. 4 Briefl y, after topical anesthesia (oxybuprocaine 0.4%, Novartis; Novartis Pharma, Milan, Italy) and chemical epithelial removal by a 20% ethanol-balanced salt solution instilled in a 7-mm optical zone maker, all eyes were treated using with the COMPex 300 laser (InPro, Norderstedt, Germany) using a Gaussian profi le laser beam. The mean depth of ablation was 96Ϯ18 µm (range: 65 to 120 µm). Immediately after treatment, MMC-treated eyes received a single topical application of MMC 0.02% (diluted with balanced salt solution) administered by placing a soaked sponge (7 mm in diameter) over the ablated stroma for 2 minutes. The corneal surface and entire conjunctival fornix were thoroughly irrigated with 20 cc of balanced salt solution. Fellow eyes did not receive MMC and underwent standard PRK and received a sponge soaked in balanced salt solution in place of MMC, with the same post-treatment procedure. After full corneal reepithelialization, all eyes were treated with artifi cial tears (hyaluronic acid 0.2%, Hyalistil; Sifi , Catania, Italy) three times daily for 3 months. Moreover, MMCtreated eyes received a placebo solution (hyaluronic acid 0.2%) three times daily for 1 month, whereas corticosteroid-treated fellow eyes received fl uorometholone sodium 2% (Flumetol S; Farmila, Milan, Italy) three times daily for 1 month. The dosage of corticosteroids and placebo was reduced to twice daily for the second month postoperatively and once daily for the third month postoperatively.
CONFOCAL MICROSCOPY
Corneal confocal microscopy was used to evaluate corneal layers in vivo. Corneal confocal microscopy was performed using a Confoscan 3.0 corneal confocal microscope (NIDEK Co Ltd, Gamagori, Japan) with a 40ϫ surface-contact objective, using a standardized technique. 4 To analyze corneal keratocyte density before and at 5 years postoperatively, fi ve stromal layers were considered, as described by Erie et al 7 : 1) 0% to 10% (anterior), 2) 11% to 33%, 3) 34% to 66%, 4) 67% to 90%, and 5) 91% to 100% (posterior) depth. One image was selected from each stromal layer for assessment of cell density. Keratocyte nuclei (cells) were identifi ed as bright objects within an area of the same size for each selected image to calculate cell density by using a custom computer program. The mean cell density in each layer after PRK was compared with the mean cell density in the corresponding layer before PRK, and the two treatment groups were also compared.
STATISTICAL ANALYSIS
Statistical analysis of variance for repeated measures was used. The F statistic is a value resulting from a standard statistical test used in analysis of variance and regression analysis to determine whether the variances between the means of two populations are signifi cantly different. For practical purposes, this value determines the P value. A P value Ͻ.01 was considered statistically signifi cant. The most anterior section showed a statistically signifi cant reduction in keratocyte density at 5-year follow-up compared to the preoperative quantifi cation (PϽ.0001 in MMC-treated eyes, PϽ.0001 in corticosteroid-treated eyes) (Figs 1 and 2 ; Table) . However, no statistically signifi cant difference was noted between groups (F=0.38, P=.54).
RESULTS
Fifty
DISCUSSION Numerous investigators have attempted to modulate corneal wound healing responses after PRK to preserve corneal clarity and the induced refractive correction. Intraoperative topical application of MMC after PRK has been introduced recently as an approach to minimize haze development. [3] [4] [5] 8 Different studies have recorded successful clinical results following PRK with MMC in treating and preventing corneal haze formation. Gambato et al 4 reported a statistically signifi cant decrease in haze formation after the prophylactic use of 0.02% MMC during PRK in highly myopic eyes. High myopes are likely the best candidates for this surgical procedure, compared to standard postoperative treatment, without any midterm signifi cant side effects. Furthermore, Gambato et al 4 confi rmed their observations using corneal confocal microscopy, which documented, for the fi rst time, the in vivo apoptotic action of MMC on stromal keratocytes.
Recently, Wilson 6 advised caution when using MMC, particularly during PRK for low to moderate myopia, because of unknown long-term effects. Our data objectively confi rm that the density of anterior corneal keratocytes is reduced in PRK MMC-treated human eyes, but this reduction is equivalent to that induced by standard PRK. Posterior corneal stroma layers did not show signs of keratocyte loss, as previously reported for standard PRK and LASIK by Erie et al. 7 Therefore, at 5-year follow-up highly myopic eyes undergoing PRK with intraoperative prophylactic topical MMC do not show signs of side effects induced by the use of 0.02% MMC. This study confi rms the relevant role of corneal confocal microscopy in the in vivo evaluation of the cornea after any refractive surgery procedure, with or without corneal wound healing modulation.
